Healthtech funding in Q3 2021
European Healthtech startup funding raised during Q3 2021.
In Q3 2021, 190 European Healthtech companies closed 192 funding rounds and raised €2.8B in equity funding (excluding debt and grants), up 39.3% versus Q3 2020. Debt rounds added €3.2M. UK led by capital raised, and Octopus Ventures was the most active investor. Data as of 20 Nov 2026.
Equity funding
€2.8B
+39.3% vs Q3 2020 · excl. debt & grants · +€3.2M debt
Funding rounds
192
+17.1% vs Q3 2020
Companies
190
Top country
UK
Rank among sectors
#5
5.6% of sector funding
Debt financing
€3.2M
0.1% of total
Top-10 round share
44.3%
of disclosed capital
Rounds ≥ €100M
3
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q3 2021 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €1.2B | 78 |
| Aug | €706M | 51 |
| Sep | €894M | 63 |
Top countries
by € raisedHealthtech — top countries by capital, Q3 2021 — interactive chart.
Data table
| Healthtech — top countries by capital, Q3 2021 | |
|---|---|
| UK | €1.6B |
| Germany | €326M |
| France | €197M |
| Switzerland | €157M |
| Sweden | €156M |
| Israel | €141M |
| Finland | €59M |
| Netherlands | €52M |
Stage mix
by € raisedHealthtech — stage mix, Q3 2021 — interactive chart.
Data table
| Healthtech — stage mix, Q3 2021 | |
|---|---|
| Other | €881M |
| Series B | €719M |
| Series D+ | €584M |
| Series C | €307M |
| Series A | €241M |
| Seed | €67M |
| Growth/Late | €14M |
| Crowdfunding | €11M |
| Pre-Seed | €4.4M |
| Grant | €3.7M |
| Debt | €3.2M |
Exits & M&A
12 Acquisition12 exits · €596M disclosed.
| Simbionix | Acquisition | Jul 2021 | €256M |
| Zebra Medical Vision | Acquisition | Aug 2021 | €171M |
| Dynamic Code | Acquisition | Sep 2021 | €148M |
| Jour | Acquisition | Sep 2021 | €17M |
| Phasya | Acquisition | Aug 2021 | €4.0M |
Top deals
largest disclosed rounds in Q3 2021| Company | Stage | Date | Amount |
|---|---|---|---|
| CMR Surgical | Series D+ | Jul 2021 | €505M |
| Artios | Series C | Jul 2021 | €130M |
| Touchlight | Other | Sep 2021 | €107M |
| Pepgen | Other | Aug 2021 | €95M |
| T-knife | Series B | Aug 2021 | €93M |
| Beckley Psytech | Series B | Aug 2021 | €68M |
| Oviva | Series C | Sep 2021 | €68M |
| Kaia Health | Other | Jul 2021 | €65M |
| Cardior Pharmaceuticals | Series B | Aug 2021 | €64M |
| TreeFrog Therapeutics | Series B | Sep 2021 | €64M |
| AIDoc | Series C | Jul 2021 | €56M |
| Quit Genius | Series B | Jul 2021 | €54M |
| Kinarus | Other | Sep 2021 | €52M |
| Lifebit | Other | Sep 2021 | €51M |
| Anjarium Biosciences | Series A | Sep 2021 | €51M |
Top investors
most active in Q3 2021, by deal count- Octopus Ventures4 deals
- Bristol Myers Squibb3 deals
- Calm Storm Ventures3 deals
- Crista Galli Ventures3 deals
- Elaia3 deals
- European Innovation Council (EIC)3 deals
- Oxford Sciences Innovation3 deals
- Scottish Enterprise3 deals
- Adage Capital Management2 deals
- Add Health Media2 deals